The Greenrose Holding Co Warrants (28/02/2024) Stock (OTC: GNRSW)

Latest news for The Greenrose Holding Co Warrants (28/02/2024) (OTC:GNRSW) Stock

Cannabis

Earnings

News

Penny Stocks

Markets

GNRS

GNRSW

Greenrose Holding&#39;s Q2 Revenue Grows 40%, Here Are The Details

The Greenrose Holding Co Warrants (28/02/2024)

<a href="https://press.aboutamazon.com/aws/2024/11/philips-and-aws-expand-strategic-collaboration-to-advance-healthsuite-cloud-services-and-power-generative-ai-workflows">https://press.aboutamazon.com/aws/2024/11/philips-and-aws-expand-strategic-collaboration-to-advance-healthsuite-cloud-services-and-power-generative-ai-workflows</a>
<a href="http://www.philips.com/newscenter">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)), a global leader in health technology, today announced the expansion of its strategic collaboration with Amazon Web Services (AWS) to offer Philips' integrated diagnostics portfolio in the cloud, including radiology, digital pathology, cardiology [1], and AI advanced visualization [1] solutions. The collaboration aims to unify diagnostic workflows, improving access to critical insights and driving better outcomes across clinical specialties. Philips has already successfully transitioned over 150 sites across North America and Latin America to <a href="https://www.usa.philips.com/healthcare/campaign/cloud-healthsuite-imaging">Philips HealthSuite Imaging</a> on AWS and is building on its collaboration with AWS to accelerate the migration of health systems to the cloud, and will expand to include customer cloud migrations in Europe.
<h2>Cloud Capabilities for Integrated Diagnostics</h2>
Philips offers scalable healthcare informatics solutions by leveraging industry-leading cloud availability, reliability and security from AWS. Philips' cloud-based solutions will offer a unified view of patient data from diverse diagnostic sources, including radiology images, digital pathology slides, and other clinical records to support care team collaboration and optimize workflows. Clinicians also benefit from remote access to diagnostic, reporting, and workflow orchestration tools, which can enhance diagnostic capabilities across healthcare imaging, from diagnosis to treatment and follow-up.
"The collaboration between Philips and AWS gives healthcare providers scalable, secure-by-design cloud-enabled solutions to accelerate healthcare innovation," said Matt Garman, CEO of AWS. "Combining Philips' healthcare informatics portfolio with AWS generative AI capabilities gives clinicians access to imaging insights so they can deliver more effective and efficient care to patients anywhere, anytime, with best-in-class security and privacy."
<h2>The Future of Workflows with Generative AI</h2>
As healthcare providers continue to face significant challenges, Philips works closely with clinicians to develop innovative ways to address the increasing clinical demands. By automating routine tasks and optimizing workflows, clinicians would be able to dedicate more time to image interpretation, consultations, and patient interactions. Philips aims to create robust and scalable generative AI applications that leverage state-of-the-art foundation models from Amazon Bedrock, and seamlessly integrate into clinical workflows. In the future, these AI applications may reduce administrative burdens and time-consuming repetitive tasks, helping clinicians focus their expertise where it matters most – in critical decision-making.
One example of how Philips is exploring generative AI as part of its innovation roadmap is through conversational reporting, allowing clinicians to use conversational language to convert findings into structured reports, which can then be reviewed. These capabilities can help construct and revise reports in real-time, add diagnostic impressions, and flag potential inconsistencies. Generative AI has the potential to reduce report editing time, while maintaining high quality by integrating patient histories and clinical context into the final diagnostic report. Optimized reporting could help lead to quicker diagnosis and support better overall quality of care.
"Given the tremendous increase not only in patient volumes, but also in the complexity and number of images per study, radiologists need a tool that limits the distractions of dictation while at the same time increasing accuracy," said Edward Steiner, Chief and Medical Director, The York/WellSpan Advanced Prostate Care Center, USA. "With Philips' concept of ambient reporting using generative AI, you simply could speak in a conversational tone and a structured report is generated within seconds. My estimate is a 15 to 20 percent increase in efficiency, and this is just the start."
"Philips' cloud-based healthcare informatics solutions allow us to drive better outcomes across clinical disciplines, including radiology, digital pathology and cardiology. We're working closely with clinicians to ensure workflows become more efficient and give back valuable time to healthcare providers," said Roy Jakobs, CEO of Royal Philips. "Collaborating with AWS helps us to innovate faster and deliver better care for more people."
<h2>Healthcare Informatics at RSNA</h2>
Philips will showcase its latest informatics solutions in the Philips booth (#6730) at the Radiological Society of North America Annual Meeting, Dec. 1-4, 2024, in Chicago, USA. For more information, visit <a href="https://www.usa.philips.com/healthcare/about/events-calendar/rsna">Philips at RSNA 2024</a>.

AMZN

Philips And AWS Expand Strategic Collaboration To Advance HealthSuite Cloud Services And Power Generative AI Workflows

<a href="https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA" title="https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA">https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA</a>.

Biotech

General

AKAN

CRON

GRWG

IMCC

LFLY

MSOS

SNDL

TLRY

DEA Says Formal Hearing Proceedings Regarding Proposed Rescheduling Of Marijuana Will Begin On Dec 2 At 9:30 a.m. ET

WIIM

Shares of rail stocks are trading lower. Weakness may be in reaction to President-elect Trump's plans for tariffs on Canada and Mexico.

In the current session, the stock is trading at $23.32, after a 1.63% spike. Over the past month, Old National Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) stock increased by 21.99%, and in the past year, by 57.39%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732650339_0.png" alt="Past Year Chart" />

<h3>A Look at Old National P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.63 in the Banks industry, Old National Inc. has a lower P/E ratio of 13.9. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732650339_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Old National

Cryptocurrency markets are trading lower on Tuesday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$91,912.69&nbsp;</td>
<td>-2.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,277.87</td>
<td>-4.8%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$226.08</td>
<td>-5.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3746</td>
<td>-6.8%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002385</td>
<td>-6.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 77.4% and daily active addresses up by 16.4%. Transactions greater than $100,000 are up from 9,585 to 13,037 in a single day. Exchanges netflows are up by 858.2%.</li>
<li>Coinglass data reports 193,074 traders were liquidated in the past 24 hours for $590.74 million.</li>
<li>CryptoQuant <a href="https://x.com/cryptoquant_com/status/1861467958851289158">noted</a> long-term holders offloaded 728,000 BTC in the past 30 days, the highest sell-off since April.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42183963/microstrategy-coinbase-and-other-bitcoin-linked-stocks-tumble-as-btcs-march-to-100000-stalls">MicroStrategy, Coinbase, And Other Bitcoin-Linked Stocks Tumble As BTC&#8217;s March To $100,000 Stalls</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42181280/crypto-billionaire-justin-sun-pledges-30m-investment-in-trump-backed-world-liberty-financial-whats-happening">Crypto Billionaire Justin Sun Pledges $30M Investment In Trump-Backed World Liberty Financial: What&#8217;s Happening?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42198180/dogecoin-gets-its-first-exchange-traded-product-in-sweden">Dogecoin Gets Its First Exchange-Traded Product In Sweden</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42180536/pro-bitcoin-trump-administration-could-see-el-salvador-emerging-as-us-strategic-partner-says-vaneck">Pro-Bitcoin Trump Administration Could See El Salvador Emerging As US &#8216;Strategic Partner,&#8217; Says VanEck</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>)</td>
<td>&nbsp;$0.5954</td>
<td>-18.6%</td>
</tr>
<tr>
<td>Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>)</td>
<td>&nbsp;$0.4344</td>
<td>-14.9%</td>
</tr>
<tr>
<td>Maker (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>)</td>
<td>&nbsp;$1,689.37&nbsp;</td>
<td>-11.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin&#8217;s recent price drop dragging the cryptocurrency market lower, chart analyst Ali Martinez highlights the availability of crypto assets at &#8220;discounts.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Black Friday came early! These are pretty good discounts. <a href="https://t.co/BJFWCdmR2U">pic.twitter.com/BJFWCdmR2U</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1861379672572870988?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to More Crypto Online, Bitcoin's correction remains in progress.
The $92,802 support hasn't been invalidated, meaning bulls could still regain momentum. 
Key support levels <a href="https://x.com/Morecryptoonl/status/1861405295232131425">include</a> $88,650, with additional Fibonacci targets at $85,558 and $77,874 if the downward trend persists.
CoinDesk senior analyst James Van Straten noted a record-breaking $4 billion in Bitcoin panic sales to exchanges, triggering liquidation cascades that allowed smart money to accumulate at discounted prices. Van Straten <a href="https://x.com/btcjvs/status/1861455973854126504">believes</a> the correction, which reached 10%, may now be complete.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History,&#8217; Crypto Surge Following It Was 3 Years Overdue</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$MKR

$SAND

$SHIB

$SOL

$XLM

Bitcoin, Ethereum, Dogecoin Drop Further: 'Black Friday Came Early,' Says Trader Touting 'Good Discounts'

<a href="https://news.delta.com/numbers-thanksgiving-holiday-travel-delta" title="https://news.delta.com/numbers-thanksgiving-holiday-travel-delta">https://news.delta.com/numbers-thanksgiving-holiday-travel-delta</a>

Delta Air Lines Says 540,000 Daily Customers On Average Expected To Fly To & From Their Thanksgiving Destination Between Nov 22 & Dec. 3

Amazon shares are trading higher after MoffettNathanson and Redburn Atlantic both maintained Buy ratings on the stock and raised their price targets.

Religion could be the next sector impacted by the rise <a href="https://www.benzinga.com/topic/artificial-intelligence">of artificial intelligence.</a>
What Happened: When it comes to the good and bad for artificial intelligence, one of the common fears is that AI will <a href="https://www.benzinga.com/news/24/04/38149277/jamie-dimon-equates-ai-to-printing-press-steam-engine-consequences-will-be-extraordinary">take people's jobs.</a>
While the job of a priest or religious figure might seem safe in the world of technology, a church in Switzerland could have other ideas.
Peter's Chapel in Lucerne, Switzerland, unveiled an "experimental art installation" that features a version of Jesus that uses artificial intelligence, as <a href="https://www.vice.com/en/article/ai-jesus-is-now-taking-confessions-at-a-church-in-switzerland/">reported </a>by Vice.
"Visitors share their thoughts and questions in a confessional with a heavenly hologram, where words are only meant for four ears — but without confession. An artificial intelligence that responds aesthetically as Jesus may create a sacred moment," the church's <a href="https://www.kathluzern.ch/mein-engagement/deus-in-machina">website </a>says.
Peter's Chapel theologian Marco Scmid said AI Jesus is an experiment that could help people have a new experience with AI. Schmid said AI Jesus can help people launch forward conversations and could have an advantage to a pastor
Schmid said AI Jesus is accessible "24 hours a day, so he has abilities that pastors don't."
Read Also: <a href="https://www.benzinga.com/tech/24/11/42145635/nvidia-ceo-jensen-huang-calls-ai-a-miracle-say-it-cant-do-100-of-our-jobs">Nvidia CEO Jensen Huang Calls AI A &#8216;Miracle,&#8217; Say It &#8216;Can&#8217;t Do 100% Of Our Jobs&#8217;</a>
Why It's Important: The church encourages visitors to "share their thoughts and questions" with their version of AI Jesus, but the process shouldn't be construed as official confession.
"Deus in machina encourages us to think critically about the limits of technology in the context of religion," the church said.
German media outlet Deutsche Well <a href="https://www.dw.com/en/switzerlands-ai-jesus-answers-questions-of-faith/video-70737962">said </a>two-thirds of participants they interviewed were impressed with the results of AI Jesus.
While AI Jesus is only a test it comes as artificial intelligence use cases continue to advance and could disrupt multiple sectors globally.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/23/04/31758131/gary-vee-warns-ai-and-chatgpt-could-take-jobs-why-he-thinks-thats-okay-and-how-its-similar-to-tracto">Gary Vee Warns AI And ChatGPT Could Take Jobs, Why He Thinks That&#8217;s Okay And How It&#8217;s Similar To Tractors</a></li>
</ul>
Courtesy: Shutterstock AI Generator

Entertainment

Global

Tech

AI Jesus Hears Confessions In Switzerland: Has Artificial Intelligence Gone Too Far?

<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41341588/donald-trumps-world-liberty-financial-token-sales-hit-220m-in-first-hour-website-faces-mul">World Liberty Financial</a>, a decentralized lending platform backed by allies of President-elect Donald Trump, has announced Tron (CRYPTO: TRON) founder Justin Sun as its new advisor.
What Happened: The decision follows <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42181280/crypto-billionaire-justin-sun-pledges-30m-investment-in-trump-backed-world-liberty-financial-whats-happening">a $30 million investment</a> by HTX, a crypto exchange closely associated with Sun, according to on-chain data.
"We are thrilled to invest $30 million in World Liberty Financial (@worldlibertyfi) as its largest investor," Sun wrote in a pinned post on X.
"The U.S. is becoming the blockchain hub, and Bitcoin owes it to @realDonaldTrump! TRON is committed to making America great again and leading innovation,&#8221; he added.
World Liberty Financial, launched in September 2014 as an Aave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>) fork, represents one of Trump's most significant ventures into cryptocurrency.
Once a vocal skeptic of digital assets, the incoming president has <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">recently embraced the industry</a>, promising to ease regulations on blockchain innovation and digital assets in the U.S.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a>
Why It Matters: The announcement comes as World Liberty's governance token sale struggles to gain momentum. Initially targeting a $300 million raise, the platform reduced its goal to $30 million in October due to limited demand.
As of Monday, World Liberty had sold $21 million worth of WLFI tokens, with sales restricted to non-U.S. and qualified U.S. investors.
Justin Sun's appointment as an advisor is expected to provide strategic direction for World Liberty Financial. 
Sun, a University of Pennsylvania graduate like Trump, has gained notoriety for high-profile investments, including <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116475/paying-6-24-million-for-a-duct-taped-banana-justin-sun-did-just-that-and-now-hell-eat-it-as-part-of-this-unique-artistic-experience">purchasing a banana duct-taped to a wall for $6.2 million</a> at a Sotheby's auction.
The firm's co-founder, Zak Folkman, commented on the relevance of these symbolic acquisitions, noting a series of recent "similarly significant purchases" aligned with Sun&#8217;s investment.
Sun's blockchain, Tron, remains one of the largest by market capitalization. 
Its TRX token initially launched as an ERC-20 standard before migrating to the native Tron network. 
Despite the announcement, TRX saw a 4.6% decline in value on Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42192364/bitcoin-correction-could-go-as-deep-as-88700-but-125000-year-end-target-remains-in-play-says-standard-chartered">Bitcoin Correction Could Go As Deep As $88,700 But $125,000 Year-End Target Remains In Play, Says Standard Chartered</a></li>
</ul>
Photo: Shutterstock

$AAVE

Trump-Linked Crypto Platform World Liberty Financial Appoints Justin Sun As Advisor After $30 Million Investment

Legislative progress on providing veterans with access to <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic therapies</a> like psilocybin, found in magic mushrooms, hit a roadblock last week as Virginia lawmakers decided not to advance a bill aimed at expanding mental health treatments for veterans. 
As Henrico Citizen <a href="https://www.henricocitizen.com/veteran-use-of-psychedelics-for-mental-health-care-still-up-in-the-air/">reported</a>, the bill, introduced by Sen. Ghazala Hashmi (D-Richmond) and Del. Michael Jones (D-Richmond), sought to create an advisory council that would study how breakthrough therapies could be used to help <a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">reduce veteran suicide rates and treat mental health disorders</a>, including post-traumatic stress disorder (PTSD). However, without further action from lawmakers, the bill was left in committee as of November 18, the deadline for bills to be considered from the previous General Assembly session.
<h3 class="wp-block-heading">The Bill</h3>
The <a href="https://lis.virginia.gov/bill-details/20251/HB80?">legislation</a> proposed a deep dive into federal regulations and licensing requirements for breakthrough therapies, which would include substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>. While the bill did not explicitly mention psilocybin, it is recognized as a potential breakthrough therapy due to its promising effects on mental health. Studies, including research from Johns Hopkins Medicine, have found that psilocybin helps alleviate symptoms of depression, anxiety and PTSD, and even aids in smoking cessation.
<h3 class="wp-block-heading">Challenges In Rescheduling Psilocybin For Medicinal Use</h3>
Despite <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">evidence supporting psilocybin&#8217;s therapeutic potential</a>, it remains a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I substance</a> in Virginia, limiting its medical use. In 2023, a <a href="https://legacylis.virginia.gov/cgi-bin/legp604.exe?231+sum+SB932=&amp;">bill</a> to reschedule it to Schedule III failed. This classification is controversial, especially considering fentanyl, another Schedule I drug, is responsible for most overdose deaths in Virginia, while psilocybin has no overdose-related fatalities.
<h3 class="wp-block-heading">Veterans Call For Better Mental Health Care And Treatment Access</h3>
Del. Jones, whose father was a Vietnam War veteran, voiced frustration at the lack of action. "Veterans deserve any form of effective mental health care they need," said Jones, emphasizing that improving mental health support for veterans should be a priority. He stressed the importance of exploring all treatment options for veterans, acknowledging the struggles some face just getting through daily life. "Every day isn't easy for everybody," Jones remarked. "For some people getting up on Thursday morning is hard as hell, and so, how do we soften that burden?"
Veterans have <a href="https://www.benzinga.com/markets/cannabis/24/10/41320243/massachusetts-veterans-advocate-for-psilocybin-legalization-will-voters-support-them">long advocated for the use of psychedelics</a> to address mental health issues, particularly PTSD, which affects a significant portion of those who have served in the military. Army veteran Anthony Mijares shared his personal testimony about the benefits of psilocybin, stating that it helped him overcome depression and reliance on prescription drugs after his military service. "The military trained me to save people, but it failed to train me on how to heal myself," Mijares said during a 2023 testimony in favor of psilocybin legislation.
Read Also:&nbsp;<a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing</a>
<h3 class="wp-block-heading">VA Funds Research On Psychedelic Treatments</h3>
In response to mounting interest in psychedelic therapies, the Department of Veterans Affairs announced in January that it <a href="https://www.benzinga.com/markets/cannabis/24/01/36523540/veterans-affairs-after-decades-will-fund-psychedelic-research-for-vets-with-ptsd-and-depression">would fund research into the use of psychedelics</a> like psilocybin to treat PTSD and depression. representing the first such VA-supported research since the 1960s.
<h3 class="wp-block-heading">The Future Of Psychedelic Treatment For Veterans In Virginia</h3>
Despite setbacks at the state level, Jones remains hopeful that future legislative efforts will prioritize veteran mental health and continue to advance research into psychedelic treatments. "We need to be bold," he said, urging that any future administration support scientific research that could improve the lives of veterans.
Whether the issue will resurface in the upcoming legislative session is still uncertain, as neither Jones nor Hashmi have confirmed plans to reintroduce the bill.
Cover image made with AI

Government

Psychedelics

Veteran Access To Psychedelic Mental Health Therapies Stalls In Virginia

INTC

Intel shares are trading lower. It was recently reported that the company's CHIPS Act grant was cut by over $600 million.

Smart Approaches to Marijuana (SAM), an active prohibitionist group, has denied allegations of improper communications with the Drug Enforcement Administration (DEA) ahead of next week&#8217;s <a href="https://www.benzinga.com/topic/cannabis-rescheduling">cannabis rescheduling</a> hearing.
SAM's Nov. 25 legal response dismissed the claims as unfounded and aimed at distracting from the proceedings, <a href="https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/">reported</a> Marijuana Moment.
The hearings, scheduled to begin Dec. 2, will explore the Department of Justice's proposed rule to reschedule cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA). The proposal follows recommendations from the U.S. Department of Health and Human Services and the Food and Drug Administration.
<h3 class="wp-block-heading">SAM Pushes Back On Collusion Allegations</h3>
The allegations, raised in a <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">joint motion</a> by cannabis company Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and veterans group Hemp for Victory, sought to disqualify SAM and the DEA from participating in the hearings. 
SAM, one of 25 designated participants, countered that the motion was a baseless attempt to smear its reputation.
"This motion is a transparent effort to smear both SAM and the DEA," SAM's lawyers, Patrick F. Philbin and Chase Harrington, wrote. 
Read Also: <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">DEA Judge Blocks Researcher&#8217;s Motion In Cannabis Rescheduling Case</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
They argued that the claims amounted to a "sideshow" and urged the DEA's Administrative Law Judge (ALJ) John J. Mulrooney to focus on the substance of the hearing.
While SAM denied any ex parte communications after the May 21 publication of the notice of proposed rulemaking (NPRM), it acknowledged earlier <a href="https://www.benzinga.com/24/11/42173101/dea-denies-allegations-of-unlawful-talks-with-anti-marijuana-group">social media posts</a> by its president, Kevin Sabet, predicting that Attorney General Merrick Garland, rather than DEA Administrator Anne Milgram, would sign the NPRM.
Critics allege that Sabet's May 6 post referencing "confidential sources inside DEA" raises questions about transparency. As for that evidence, SAM's lawyers argued the post was made before the NPRM's issuance.
<h3 class="wp-block-heading">A Related Case</h3>
The same DEA judge leading this case has recently denied the <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">request</a> by research company <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">MedPharm</a> to participate in the December 2 hearing, citing his limited authority and deferring to the DEA Administrator&#8217;s discretion over participant selection.
MedPharm criticized the exclusion of DEA-licensed marijuana researchers and the inclusion of prohibitionist groups, calling the process biased and undermining its legitimacy. 
Critics worry the imbalance in witness selection could skew the hearing&#8217;s outcomes, despite support from other federal agencies for rescheduling.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/24/11/42173101/dea-denies-allegations-of-unlawful-talks-with-anti-marijuana-group">DEA Denies Allegations Of Colluding With Anti-Marijuana Group While Involved In Cannabis Rescheduling Process</a></li>
</ul>
COVER: AI-Generated image

Regulations

Politics

Prohibitionist Group Denies Collusion Allegations Ahead Of DEA Cannabis Rescheduling Hearing

Federal Reserve policymakers unanimously decided to reduce interest rates by 25 basis points to a range of 4.5%-4.75% during their November meeting, as they expressed confidence that inflation was moving sustainably toward their 2% target, according to <a href="https://www.benzinga.com/topic/interest-rates">meeting minutes released Wednesday.</a>
Participants highlighted several factors expected to maintain downward pressure on inflation, including diminishing business pricing power, the Fed&#8217;s restrictive monetary policy stance, and well-anchored long-term inflation expectations. 
<h3 class="wp-block-heading">Easing Inflation, But Core Pressures Persist</h3>
The minutes revealed that nearly all participants believed the latest data supported the view that inflation was steadily moderating, albeit with volatility in month-to-month readings. 
Inflation, they noted, had eased significantly from its peak. However, core inflation measures—excluding volatile food and energy prices—remained &#8220;somewhat elevated.&#8221;
Policymakers also discussed upside risks to inflation, including potential disruptions in global supply chains due to geopolitical events, a faster-than-anticipated loosening of financial conditions, unexpectedly robust consumer spending, persistent shelter price increases, and surging insurance costs across health, automotive, and housing sectors.
<h3 class="wp-block-heading">Resilient Economy and Labor Market Underpin Consumer Spending</h3>
Economic data reviewed at the meeting pointed to stronger-than-expected growth in consumer spending and overall economic activity. 
While participants generally agreed that the labor market remained solid, they emphasized the importance of closely monitoring indicators for signs of softening, which could influence the Fed&#8217;s future policy direction.
&#8220;Participants remarked that consumption had been supported by a solid labor market, rising real wages, and elevated household wealth,&#8221; the minutes stated. &nbsp;
<h3 class="wp-block-heading">Diverging Views on Monetary Policy Adjustments</h3>
The minutes also shed light on varying perspectives regarding the Fed&#8217;s next steps. 
While some participants suggested the central bank could pause its easing cycle and hold rates at restrictive levels if inflation remained sticky, others indicated that policy easing could be accelerated if economic conditions weakened, such as a downturn in the labor market or a notable slowdown in economic activity.
&#8220;Many participants observed that uncertainties concerning the level of the neutral rate of interest complicated the assessment of the degree of restrictiveness of monetary policy and, in their view, made it appropriate to reduce policy restraint gradually,&#8221; according to the November minutes. 
<h3 class="wp-block-heading">Market Reactions</h3>
The release of the Fed meeting minutes had little impact on short-term interest rate markets. 
Fed funds futures continued to show a 59% probability of another 25-basis-point rate cut in December, unchanged from market expectations prior to the minutes&#8217; publication.
The U.S. dollar index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), held steady, gaining 0.2% on the day. Meanwhile, Treasury yields saw marginal changes, with the 10-year Treasury yield broadly holding at 4.32%.
The S&amp;P 500 index – tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – also held its marginal session gains, up 0.3%. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42194139/consumer-confidence-hits-2-year-high-as-recession-fears-fade-stock-market-optimism-soars-to-record-high">Consumer Confidence Hits 2-Year High As Recession Fears Fade: Stock Market Optimism Soars To Record High</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Minutes Reveal 'Confidence' In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead

Whales with a lot of money to spend have taken a noticeably bullish stance on Constellation Energy.
Looking at options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) we detected 52 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $281,144 and 47, calls, for a total amount of $2,195,419.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $360.0 for Constellation Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Constellation Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Constellation Energy's whale trades within a strike price range from $180.0 to $360.0 in the last 30 days. 
<h3>Constellation Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649511_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.4</td>
<td>$300.00</td>
<td>$128.0K</td>
<td>4.1K</td>
<td align="right">440</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.0</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$280.00</td>
<td>$115.4K</td>
<td>782</td>
<td align="right">342</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.5</td>
<td>$17.2</td>
<td>$17.85</td>
<td>$250.00</td>
<td>$107.6K</td>
<td>859</td>
<td align="right">447</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.7</td>
<td>$19.3</td>
<td>$21.0</td>
<td>$210.00</td>
<td>$105.0K</td>
<td>21</td>
<td align="right">50</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$24.3</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$260.00</td>
<td>$101.2K</td>
<td>271</td>
<td align="right">45</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
Following our analysis of the options activities associated with Constellation Energy, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Constellation Energy</h3>
<ul>
<li>Currently trading with a volume of 2,588,934, the CEG's price is up by 5.87%, now at $263.55. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 91 days.</li>
</ul>
<h3>Professional Analyst Ratings for Constellation Energy</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $283.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Constellation Energy with a target price of $270. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Constellation Energy, maintaining a target price of $291. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Constellation Energy, maintaining a target price of $322. 
&#x2A; An analyst from Mizuho persists with their Neutral rating on Constellation Energy, maintaining a target price of $235. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Constellation Energy, which currently sits at a price target of $298. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Constellation Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Constellation Energy's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SAVA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Cassava Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 44% bearish. Among these notable options, 14 are puts, totaling $1,005,809, and 4 are calls, amounting to $358,518.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.5 to $50.0 for Cassava Sciences over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cassava Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cassava Sciences's whale activity within a strike price range from $2.5 to $50.0 in the last 30 days. 
<h3>Cassava Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649506_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.45</td>
<td>$16.3</td>
<td>$16.42</td>
<td>$20.00</td>
<td>$328.3K</td>
<td>2.8K</td>
<td>57</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.6</td>
<td>$1.21</td>
<td>$1.25</td>
<td>$5.00</td>
<td>$234.6K</td>
<td>675</td>
<td>2.0K</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.45</td>
<td>$16.3</td>
<td>$16.4</td>
<td>$20.00</td>
<td>$136.1K</td>
<td>2.8K</td>
<td>362</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.0</td>
<td>$13.85</td>
<td>$13.85</td>
<td>$17.50</td>
<td>$74.7K</td>
<td>5.2K</td>
<td>54</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$12.0</td>
<td>$11.5</td>
<td>$12.0</td>
<td>$16.00</td>
<td>$60.0K</td>
<td>103</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
In light of the recent options history for Cassava Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Cassava Sciences</h3>
<ul>
<li>With a trading volume of 25,393,267, the price of SAVA is down by -6.4%, reaching $4.02.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 92 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cassava Sciences</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $116.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Neutral, setting a price target of $116. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $116. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cassava Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SAVA

Unpacking the Latest Options Trading Trends in Cassava Sciences

Investors with a lot of money to spend have taken a bullish stance on STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with STM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for STMicroelectronics.
This isn't normal.
The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $431,012, and 8 are calls, for a total amount of $668,404.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $21.0 and $27.0 for STMicroelectronics, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of STMicroelectronics stands at 573.64, with a total volume reaching 11,435.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in STMicroelectronics, situated within the strike price corridor from $21.0 to $27.0, throughout the last 30 days.
<h3>STMicroelectronics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649500_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.9</td>
<td>$5.8</td>
<td>$5.9</td>
<td>$21.00</td>
<td>$156.3K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$22.00</td>
<td>$143.1K</td>
<td align="right">92</td>
<td align="right">265</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$23.00</td>
<td>$111.3K</td>
<td align="right">60</td>
<td align="right">1</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$24.00</td>
<td>$62.2K</td>
<td align="right">949</td>
<td align="right">270</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.1</td>
<td>$5.9</td>
<td>$6.1</td>
<td>$21.00</td>
<td>$59.7K</td>
<td align="right">2</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About STMicroelectronics</h3>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
After a thorough review of the options trading surrounding STMicroelectronics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of STMicroelectronics</h3>
<ul>
<li>With a trading volume of 3,820,555, the price of STM is up by 1.79%, reaching $26.21.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On STMicroelectronics</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $33.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Craig-Hallum persists with their Buy rating on STMicroelectronics, maintaining a target price of $36. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on STMicroelectronics, maintaining a target price of $33. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on STMicroelectronics, which currently sits at a price target of $30. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on STMicroelectronics, maintaining a target price of $33. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for STMicroelectronics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

STMicroelectronics Unusual Options Activity For November 26

BSFC

Blue Star Foods shares are trading higher after the company announced a $1.5 million buyback program.

Buybacks

Blue Star Foods Announces $1.5M Stock Buyback Program

<a href="https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says" title="https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says">https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says</a>

Chevron Exec Says "Chevron Is Concerned By The Recent Committee And Assembly Passages Of Assembly Bill X2-1"; New California Legislation Can Have Negative Impact On California's Energy Infrastructure

Shares of housing and building-related stocks are trading lower. Building permits and new home sales fell in October.

The Greenrose Holding Company Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GNRS#OTCQX">GNRS</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GNRSW#OTC">GNRSW</a>) released financial and operating results for the second quarter ended June 30, 2022, revealing revenue, net of discounts increased 40% to $9.2 million compared to $6.6 million in the prior year quarter.

The increase in revenue primarily reflects incremental revenue contributions from True Harvest compared to the prior year period, which only included contributions from Theraplant. Theraplant&rsquo;s second quarter revenues decreased year-over year as a result of sustained demand headwinds in Connecticut&rsquo;s medical market, as well as increased competition and impacts from the state&rsquo;s illicit market. True Harvest&rsquo;s second quarter revenue performance continues to reflect the impacts of production disruptions resulting from the facility&rsquo;s recent expansion.

Q2 2022 Financial Highlights

<ul>
	<li>
	Gross profit was $2.9 million compared to $4.4 million in the prior year quarter.
	</li>
</ul>

<ul>
	<li>
	Net loss was $10.3 million compared to net income of $3.3 million in the prior year quarter.
	</li>
	<li>
	Adjusted EBITDA was $3.1 million compared to $4.6 million in the prior year quarter.
	</li>
	<li>
	Cash and cash equivalents combined with restricted cash was $2.7 million at June 30, 2022 compared to $9.1 million at December 31, 2021.
	</li>
</ul>

&ldquo;During the second quarter, we continued to strengthen our operational foundation in both Connecticut and Arizona,&rdquo; stated Mickey Harley, CEO of Greenrose. &ldquo;Our revenues increased 40% year-over-year due to incremental contributions from True Harvest, where we substantially reduced our inventory backlog and generated sequential month-over-month sales improvements. At Theraplant, we continued to navigate demand headwinds within the state&rsquo;s current medical market, but worked to further activate our increased cultivation capacity and build inventory ahead of Connecticut&rsquo;s expected commencement of recreational cannabis sales.&rdquo;

&ldquo;While we continued to incur higher costs associated with ramping our expanded cultivation capacity at both True Harvest and Theraplant, we believe this work improves our positioning for improving our operations in Arizona and preparing for Connecticut&rsquo;s forthcoming recreational market, respectively. As we progress into the second half of 2022, we remain focused on leveraging our existing production efficiencies to deepen and expand our presence in our existing state markets,&rdquo; continued Harley.

2022 Financial Outlook Update 
Due to regulatory delays surrounding the expected timing of Connecticut&rsquo;s recreational cannabis market, Greenrose is suspending its previously stated full year 2022 guidance. The company expects to re-evaluate and provide further updates on its 2022 outlook as regulatory visibility improves.

Related News

<a href="https://www.benzinga.com/markets/cannabis/22/08/28411197/as-curaleaf-taps-ex-jushi-clever-leaves-executives-other-big-cannabis-players-also-make-key-lead" target="_blank">As Curaleaf Taps Ex Jushi &amp; Clever Leaves Executives Other Big Cannabis Players Also Make Key Leadership Changes</a>

<a href="https://www.benzinga.com/markets/cannabis/22/01/24864162/greenrose-holdings-stock-jumps-on-closing-57-6m-acquisition-of-arizona-craft-cannabis-producer" target="_blank">Greenrose Holding&#39;s Stock Jumps On Closing $57.6M Acquisition Of Arizona Craft Cannabis Producer</a>

Comments

The Greenrose Holding Co Warrants (28/02/2024)

News

Latest news for The Greenrose Holding Co Warrants (28/02/2024) (OTC:GNRSW) Stock

Tuesday, August 23, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga